Inulin-based nanoparticles for targeted siRNA delivery in acute kidney injury

IF 10.5 1区 医学 Q1 CHEMISTRY, MULTIDISCIPLINARY Journal of Controlled Release Pub Date : 2024-10-24 DOI:10.1016/j.jconrel.2024.10.027
Chinmay M. Jogdeo , Sudipta Panja , Neha Kumari , Weimin Tang , Ekta Kapoor , Kasturi Siddhanta , Ashish Das , Erika I. Boesen , Kirk W. Foster , David Oupický
{"title":"Inulin-based nanoparticles for targeted siRNA delivery in acute kidney injury","authors":"Chinmay M. Jogdeo ,&nbsp;Sudipta Panja ,&nbsp;Neha Kumari ,&nbsp;Weimin Tang ,&nbsp;Ekta Kapoor ,&nbsp;Kasturi Siddhanta ,&nbsp;Ashish Das ,&nbsp;Erika I. Boesen ,&nbsp;Kirk W. Foster ,&nbsp;David Oupický","doi":"10.1016/j.jconrel.2024.10.027","DOIUrl":null,"url":null,"abstract":"<div><div>RNA interference has emerged as a promising therapeutic strategy to tackle acute kidney injury (AKI). Development of targeted delivery systems is highly desired for selective renal delivery of RNA and improved therapeutic outcomes in AKI. Inulin is a plant polysaccharide traditionally employed to measure glomerular filtration rate. Here, we describe the synthesis of inulin modified with α-cyclam-<em>p</em>-toluic acid (CPTA) to form a novel renal-targeted polymer, Inulin-CPTA (IC), which is capable of selective siRNA delivery to the injured kidneys. We show that conjugating CPTA to inulin imparts IC with targeting properties for cells that overexpress the C-X-C chemokine receptor 4 (CXCR4). Self-assembled IC/siRNA nanoparticles (polyplexes) demonstrated rapid accumulation in the injured kidneys with selective uptake and prolonged retention in injured renal tubules overexpressing the CXCR4 receptor. Tumor-suppressor protein p53 contributes significantly to the pathogenesis of AKI. siRNA-induced silencing of p53 has shown therapeutic potential in several preclinical studies, making it an important target in the treatment of AKI. Systemically administered nanoparticles formulated using IC and siRNA against p53 selectively accumulated in the injured kidneys and potently silenced p53 expression. Selective p53 knockdown led to positive therapeutic outcomes in mice with cisplatin-induced AKI, as seen by reduced tubular cell death, renal injury, inflammation, and overall improved renal function. These findings indicate that IC is a promising new carrier for renal-targeted delivery of RNA for the treatment of AKI.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"376 ","pages":"Pages 577-592"},"PeriodicalIF":10.5000,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Controlled Release","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0168365924007004","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0

Abstract

RNA interference has emerged as a promising therapeutic strategy to tackle acute kidney injury (AKI). Development of targeted delivery systems is highly desired for selective renal delivery of RNA and improved therapeutic outcomes in AKI. Inulin is a plant polysaccharide traditionally employed to measure glomerular filtration rate. Here, we describe the synthesis of inulin modified with α-cyclam-p-toluic acid (CPTA) to form a novel renal-targeted polymer, Inulin-CPTA (IC), which is capable of selective siRNA delivery to the injured kidneys. We show that conjugating CPTA to inulin imparts IC with targeting properties for cells that overexpress the C-X-C chemokine receptor 4 (CXCR4). Self-assembled IC/siRNA nanoparticles (polyplexes) demonstrated rapid accumulation in the injured kidneys with selective uptake and prolonged retention in injured renal tubules overexpressing the CXCR4 receptor. Tumor-suppressor protein p53 contributes significantly to the pathogenesis of AKI. siRNA-induced silencing of p53 has shown therapeutic potential in several preclinical studies, making it an important target in the treatment of AKI. Systemically administered nanoparticles formulated using IC and siRNA against p53 selectively accumulated in the injured kidneys and potently silenced p53 expression. Selective p53 knockdown led to positive therapeutic outcomes in mice with cisplatin-induced AKI, as seen by reduced tubular cell death, renal injury, inflammation, and overall improved renal function. These findings indicate that IC is a promising new carrier for renal-targeted delivery of RNA for the treatment of AKI.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
基于菊粉的纳米颗粒在急性肾损伤中靶向递送 siRNA。
RNA 干扰已成为应对急性肾损伤(AKI)的一种前景广阔的治疗策略。为了选择性地向肾脏输送 RNA 并改善 AKI 的治疗效果,开发靶向输送系统是非常必要的。菊粉是一种植物多糖,传统上用于测量肾小球滤过率。在这里,我们描述了菊粉与α-环戊酸(CPTA)的合成,从而形成一种新型肾脏靶向聚合物--菊粉-CPTA(IC),它能够选择性地将 siRNA 运送到受伤的肾脏。我们的研究表明,将 CPTA 与菊粉共轭可使 IC 对过度表达 C-X-C 趋化因子受体 4(CXCR4)的细胞具有靶向特性。自组装的IC/siRNA纳米颗粒(多聚体)在损伤的肾脏中迅速积累,并在过度表达CXCR4受体的损伤肾小管中被选择性摄取和长时间保留。siRNA 诱导的 p53 沉默已在多项临床前研究中显示出治疗潜力,使其成为治疗 AKI 的重要靶点。使用 IC 和 siRNA 针对 p53 配制的全身给药纳米颗粒可选择性地在损伤的肾脏中聚集,并有效地抑制 p53 的表达。在顺铂诱导的 AKI 小鼠中,选择性地敲除 p53 会带来积极的治疗效果,表现为肾小管细胞死亡、肾损伤、炎症的减少以及肾功能的整体改善。这些研究结果表明,IC 是一种很有前景的新载体,可用于肾脏靶向递送 RNA 以治疗 AKI。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Controlled Release
Journal of Controlled Release 医学-化学综合
CiteScore
18.50
自引率
5.60%
发文量
700
审稿时长
39 days
期刊介绍: The Journal of Controlled Release (JCR) proudly serves as the Official Journal of the Controlled Release Society and the Japan Society of Drug Delivery System. Dedicated to the broad field of delivery science and technology, JCR publishes high-quality research articles covering drug delivery systems and all facets of formulations. This includes the physicochemical and biological properties of drugs, design and characterization of dosage forms, release mechanisms, in vivo testing, and formulation research and development across pharmaceutical, diagnostic, agricultural, environmental, cosmetic, and food industries. Priority is given to manuscripts that contribute to the fundamental understanding of principles or demonstrate the advantages of novel technologies in terms of safety and efficacy over current clinical standards. JCR strives to be a leading platform for advancements in delivery science and technology.
期刊最新文献
Interaction design in mRNA delivery systems Channel-assembling tumor microenvironment on-chip for evaluating anticancer drug efficacy Corrigendum to “Golgi-customized Trojan horse nanodiamonds impair GLUT1 plasma membrane localization and inhibit tumor glycolysis [371 (2024) 338–350]” Cellulose nanocrystal-annealed hydrogel system for local chemo-metabolic therapy of melanoma Modulation of GABAergic neurons in acute epilepsy using sonogenetics
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1